On February 2, 2026, FDA's Quality Management System Regulation (QMSR) replaced the legacy Quality System Regulation (QSR) under 21 CFR Part 820. The QMSR incorporates ISO 13485:2016 by reference and fundamentally expands risk management requirements beyond design controls to every part of a manufacturer's quality system. If your risk management program still looks like it did under the old QSR, it is no longer compliant. This article explains exactly what QMSR demands, how ISO 14971:2019 fits in, what a complete risk management file looks like, and the most common gaps FDA investigators find in 2026.

What QMSR Now Requires for Risk Management

The QMSR, which took effect on February 2, 2026, represents the most significant overhaul of U.S. medical device quality regulations in decades. The rule amends 21 CFR Part 820 by incorporating ISO 13485:2016 by reference, replacing the prescriptive QSR subsystem requirements with the internationally recognized framework used by regulators in the EU, Canada, Japan, Brazil, and Australia. (FDA)

Under QMSR, risk management is no longer a design-phase activity. ISO 13485:2016 requires manufacturers to apply a risk-based approach across the entire quality management system, as described in Subclause 4.1.2. That means risk thinking must inform decisions in purchasing, production, complaint handling, supplier qualification, corrective and preventive actions, and every other process within the QMS.

FDA's official definition of risk, drawn directly from ISO 13485, is: the combination of the probability of occurrence of harm and the severity of that harm. This definition governs how manufacturers must frame, document, and evaluate all risk-related decisions throughout the product lifecycle.

The QMSR also requires manufacturers to document their risk-based decisions as part of QMS documentation, maintained per ISO 13485 Subclause 4.2.5. Undocumented risk decisions are, in the eyes of an FDA investigator, decisions that were never made.

ISO 13485:2016 Incorporation by Reference: What It Means for Risk

Before the QMSR, 21 CFR Part 820 contained its own written requirements for each QMS element. The new Part 820 is dramatically shorter. Most requirements now appear as references to specific clauses of ISO 13485:2016, the full text of which manufacturers must have and follow.

For risk management, the relevant ISO 13485 clauses are:

• Clause 4.1.2 requires a risk-based approach to control of QMS processes.
• Clause 7.1 requires risk management to be addressed during product realization planning.
• Clause 7.3 connects risk management to design and development.
• Clause 7.4 applies risk thinking to purchasing processes, meaning supplier risk must be evaluated and documented.
• Clause 8.2.1 requires feedback from post-market surveillance to serve as input into risk management.
• Clause 8.4 requires data analysis to demonstrate the suitability and effectiveness of the QMS.
• Clause 8.5.1 requires the manufacturer to identify and implement changes necessary for continued safety and performance.

This framework demands a living, connected risk management system, not a one-time design phase exercise. Post-market data must flow back into your risk files. Supplier risk must be evaluated and re-evaluated. Process risk must inform how you control and monitor production.

QMSR Risk Management vs. the Old QSR: Key Differences

Under the old QSR, risk analysis was primarily located in 21 CFR 820.30(g), tied to design controls. Risk analysis was largely a design-phase deliverable. The scope of risk management was narrower, inspection was more procedural, and the QSIT inspection technique focused on defined subsystems independently.

QMSR changes this in three important ways.

First, risk management now spans the entire QMS. FDA's January 2026 Town Hall on QMSR risk and design topics made clear that even Class I devices exempt from design controls must maintain records of risk management activities for production processes, purchasing, and labeling. (FDA Town Hall, January 14, 2026)

Second, FDA's inspection approach changed on the same day the QMSR took effect. The agency replaced the QSIT technique with Compliance Program 7382.850, a risk-driven, lifecycle-focused inspection model. Investigators now evaluate end-to-end risk controls holistically, not as isolated subsystems.

Third, management review records are now inspectable. Under the old QSR, they were explicitly exempt. Under QMSR, FDA investigators can request and review them. Any candid language, incomplete documentation, or unresolved action items in those records becomes inspection evidence.

The shift in expectation is significant: where the old QSR asked "do you have a procedure?", QMSR asks "can you demonstrate that risk-based decisions were made consistently across your entire QMS?"

ISO 14971:2019 and QMSR: The Practical Alignment

FDA made clear at the January 2026 Town Hall that ISO 14971 is not a mandatory requirement under QMSR. There is no QMSR clause that explicitly mandates conformity to ISO 14971. Manufacturers may use any validated risk management process appropriate for their device and QMS.

However, the practical reality is this: ISO 14971:2019 is the gold standard framework for medical device risk management, and without a process of equivalent rigor, demonstrating that your risk management is effective, systematic, and defensible is extremely difficult. FDA investigators will probe the logic of your risk decisions. If you cannot point to a structured framework, the burden of proof rests entirely on you.

ISO 14971:2019, the third edition of the standard, was confirmed current in 2025 and represents the most comprehensive version to date. It applies to all types of risks throughout the device lifecycle, from conception through decommissioning, and specifically covers software as a medical device (SaMD) and in vitro diagnostic devices.

For manufacturers seeking QMSR compliance while maintaining global market access, ISO 14971:2019 combined with ISO 13485:2016 provides a dual-compliance architecture that satisfies FDA, MDR, Health Canada, and most other major regulatory frameworks simultaneously.

The ISO 14971:2019 Risk Management Process

The ISO 14971:2019 process consists of five core activities that form a closed loop across the product lifecycle.

Risk Analysis

Risk analysis starts with the intended use and reasonably foreseeable misuse of the device. The manufacturer identifies all hazards associated with the device, determines the hazardous situations that could arise from each hazard, and estimates the risk for each hazardous situation. A Hazard Analysis is typically the primary output, with supporting tools like Failure Mode and Effects Analysis (FMEA) providing structured documentation of potential failure modes, their causes, effects, current controls, and risk levels.

Risk Evaluation

Once risks are estimated, the manufacturer evaluates each against pre-defined risk acceptability criteria. These criteria must be established in the risk management plan before analysis begins. ISO 14971 does not specify acceptable risk levels, since acceptability depends on device type, intended patient population, and clinical benefit context. What the standard requires is objective, documented criteria and a consistent methodology for applying them.

Risk Control

When a risk is judged unacceptable, the manufacturer must implement controls using a strict priority hierarchy:

1. Inherently safe design (eliminate or reduce the hazard at source)
2. Protective measures in the device or manufacturing process
3. Information for safety (labels, warnings, instructions for use)

Risk controls must be verified for effectiveness. New hazards introduced by the controls themselves must be identified and evaluated. This is an area where many manufacturers fall short: they implement a control but fail to assess whether the control created a new or modified risk.

Residual Risk Evaluation

After controls are implemented, the residual risk for each hazard must be evaluated against the acceptability criteria. If the residual risk remains unacceptable and further risk reduction is not practicable, the manufacturer must weigh the residual risk against the clinical benefit of the device. This benefit-risk analysis must be documented.

The overall residual risk must then be evaluated in totality. Even if individual residual risks are acceptable, the aggregate residual risk across the device may not be.

Risk Management Report

The risk management report is the formal summary that ties the entire process together. It confirms that the risk management plan was executed, all identified risks were evaluated, the overall residual risk is acceptable, and appropriate post-production information collection methods are in place. This report is a required output of ISO 14971 and a critical component of the risk management file.

What a Complete Risk Management File Contains

The risk management file (RMF) is the organized collection of documents and records that demonstrate a manufacturer's risk management activities for a specific device. Under both ISO 14971 and QMSR, the RMF must be traceable, complete, and maintained throughout the product lifecycle.

A compliant risk management file typically includes:

• Risk management plan: Scope, intended use, life cycle phases covered, risk acceptability criteria, and responsibilities.
• Hazard identification records: Comprehensive list of hazards and hazardous situations derived from intended use analysis.
• Risk estimation records: For each hazardous situation, the estimated probability of harm and severity, with supporting rationale.
• Risk evaluation records: Comparison of estimated risks to acceptability criteria, with documented decisions for each.
• Risk control records: Description of selected controls, verification of effectiveness, and evaluation of any new risks introduced.
• Residual risk evaluation: Post-control risk assessments and benefit-risk analysis where required.
• Risk management report: Summary document confirming plan execution, risk acceptability, and post-production monitoring methods.
• Post-market surveillance records: Evidence that post-market data is fed back into risk management per ISO 13485 Clauses 8.2.1 and 8.5.1.

The Risk Register functions as the living backbone of the RMF, aggregating risks across the device and QMS processes in a single, auditable record.

Every document in the risk management file must carry an Audit Trail, showing who created, reviewed, and approved each record and when. Under 21 CFR Part 11 requirements, if your QMS is electronic, electronic signatures and records must comply with FDA's electronic record requirements.

Common QMSR Risk Management Gaps at FDA Inspections

As FDA investigators begin operating under CP 7382.850 and QMSR, certain deficiency patterns are already emerging. Quality Directors and Regulatory Affairs Managers should conduct gap assessments against these areas before the next inspection.

Risk management confined to design controls. The most prevalent gap is treating risk management as a design-phase-only activity. QMSR requires risk-based thinking across complaints, supplier qualification, production processes, and corrective actions. If your Deviation CAPA process does not include a documented risk-based prioritization decision, that is a gap.

Undocumented risk-based decisions. FDA's Town Hall guidance was explicit: risk-based decisions must be documented in QMS records. A complaint investigation that differentiates between a packaging defect and a patient harm complaint is exercising risk-based thinking. If that differentiation is not documented, it cannot be demonstrated during an inspection. Audit Finding records that do not reflect the risk-based rationale for corrective action timing or scope are another common observation.

No post-market feedback loop into risk management. ISO 13485 Clauses 8.2.1 and 8.5.1 require that post-market data informs the risk management process. Many manufacturers have complaint handling procedures and post-market surveillance programs, but no documented mechanism connecting post-market data back to their risk files. This traceability gap is increasingly cited at inspections.

Missing or incomplete risk management files. The risk management file must exist as an organized collection, not a scattered set of documents across different folders or systems. Missing risk management reports, unapproved hazard analysis records, or unverified risk controls are among the most direct pathways to an FDA Form 483 observation.

Risk acceptability criteria not established in advance. Defining acceptability criteria after risk analysis is complete is a significant procedural violation. The criteria must be in the risk management plan before hazard analysis begins.

Supplier risk not evaluated or documented. ISO 13485 Clause 7.4 applies risk thinking to purchasing. Under QMSR, if you have outsourced critical processes or use critical suppliers, there must be documented risk evaluations supporting your supplier qualification and monitoring decisions.

Root Cause Investigation records disconnected from risk management. When a nonconformance triggers a root cause investigation, the findings should feed back into the risk management file if they reveal a new hazard or previously underestimated risk. Systems where CAPA and risk management operate in silos fail this expectation.

How an eQMS Supports 21 CFR Part 820 Risk Management

Managing QMSR risk management requirements manually or across disconnected spreadsheets is increasingly untenable. Risk data lives across multiple device files, supplier records, production nonconformances, complaints, and management reviews. Without a connected system, demonstrating end-to-end traceability to an FDA investigator is extremely difficult.

An electronic QMS (eQMS) built for QMSR and ISO 13485 dual compliance closes this gap by connecting risk management to every relevant QMS process in a single platform.

Cloudtheapp's Enterprise Risk Management application provides a centralized environment for building and maintaining risk management files, tracking risk controls, and documenting residual risk evaluations with full audit trail support. The platform's Hazard Analysis and FMEA tools guide users through the ISO 14971:2019 process step by step, ensuring that risk analysis, evaluation, control, and reporting activities are structured, linked, and version-controlled.

The Risk Assessments module connects directly to Design Controls, so design changes automatically trigger risk impact evaluations, keeping the risk management file current throughout the product development lifecycle. Supplier risk records in the Supplier Qualification Management module link to the purchasing risk evaluation requirements of ISO 13485 Clause 7.4, creating the documented evidence FDA expects.

Post-market surveillance data from complaints, deviations, and nonconforming material records feeds back into the risk management environment automatically, satisfying the ISO 13485 Clauses 8.2.1 and 8.5.1 loop that FDA now actively inspects.

Because Cloudtheapp is a fully validated platform compliant with 21 CFR Part 820 (QMSR), ISO 13485:2016, and ISO 9001, manufacturers can maintain their own QMS compliance while operating on infrastructure that already satisfies FDA's Computer System Validation requirements. Every update comes with a complete validation package, removing the burden of managing platform compliance in-house.

Conclusion

QMSR risk management is not a design controls update. It is a fundamental shift in how risk thinking must be embedded across every element of a medical device manufacturer's quality system. With FDA inspections now operating under CP 7382.850 and ISO 13485:2016 as the binding framework, manufacturers who treat risk management as a pre-market exercise will face growing inspection risk.

The ISO 14971:2019 process remains the most rigorous and defensible framework available, and the combination of ISO 14971 and ISO 13485 provides the strongest foundation for both FDA and global regulatory compliance.

For Quality Directors, Regulatory Affairs professionals, and Risk Managers navigating this transition, the starting point is a documented gap assessment: where does risk-based thinking exist in your QMS today, where is it absent, and what records demonstrate that risk decisions were made intentionally and consistently?

If you are building or restructuring your QMSR risk management program, request a demo at cloudtheapp.com to see how Cloudtheapp's validated eQMS platform supports end-to-end 21 CFR Part 820 risk management, from hazard analysis and FMEA through post-market surveillance feedback and audit-ready documentation.

This post created by and appeared first on Cloudtheapp

Process Hazard Analysis (PHA) is a structured, systematic methodology used to identify, evaluate, and control hazards in processes that involve hazardous chemicals or complex operational sequences. Mandated by OSHA's Process Safety Management standard, the EPA Risk Management Program, and referenced across FDA and ICH Q9 quality frameworks, PHA is a compliance cornerstone for pharmaceutical manufacturers, medical device companies, chemical processors, and food producers. This guide covers the definition, regulatory context, major PHA methods, life sciences applications, step-by-step execution, QMS integration, and the documentation gaps that most teams overlook.

What Is Process Hazard Analysis?

Process Hazard Analysis, commonly abbreviated as PHA, is an organized effort to identify and evaluate hazards associated with chemical processes or operations. A PHA examines what can go wrong in a process, how likely it is, and what the consequences might be, then identifies safeguards that prevent or mitigate those outcomes.

PHA applies wherever hazardous materials or energies are present: pharmaceutical API synthesis, sterile fill-finish operations, chemical batch reactors, food processing lines, medical device assembly, and more.

The Regulatory Context: Why PHA Is Mandated

OSHA Process Safety Management (29 CFR 1910.119)

The Occupational Safety and Health Administration's Process Safety Management of Highly Hazardous Chemicals standard, codified at 29 CFR 1910.119, makes PHA a mandatory element of any PSM program. Under 29 CFR 1910.119(e), employers must perform an initial PHA on all covered processes and revalidate each PHA at least every five years. The standard specifies that the team must include at least one employee with process engineering expertise and one with operations experience.

EPA Risk Management Program (40 CFR Part 68)

The EPA's Risk Management Program requires facilities that handle regulated substances above threshold quantities to develop and implement a Risk Management Plan. Program 3 processes under EPA RMP must conduct a PHA equivalent to OSHA's PSM requirements.

FDA HACCP and Food Safety

The Food and Drug Administration's Hazard Analysis and Critical Control Points framework, referenced in 21 CFR Part 123 and Part 120 and more broadly through FDA Food Safety Modernization Act (FSMA) preventive controls requirements, applies PHA principles to food safety. FDA's HACCP guidance frames hazard analysis as the foundation of every food safety plan.

ICH Q9: Quality Risk Management in Pharmaceuticals

The International Council for Harmonisation's Q9(R1) guideline on Quality Risk Management, adopted by the FDA and published in May 2023, provides the overarching framework for risk management across the pharmaceutical product lifecycle. ICH Q9(R1) explicitly identifies HAZOP and FMEA as recognized risk assessment tools for pharmaceutical applications.

ISO 14971 for Medical Devices

For medical device manufacturers, ISO 14971:2019 specifies requirements for a risk management process that applies PHA principles throughout the entire device lifecycle. The standard mandates a Risk Management File that documents each identified hazard, its estimated probability and severity, the risk control measures applied, and residual risk acceptability.

Types of Process Hazard Analysis Methods

Hazard and Operability Study (HAZOP)

HAZOP is the most widely used PHA method in the chemical, pharmaceutical, and process industries. It applies standardized guide words, such as "No," "More," "Less," "Reverse," and "Other Than," to process parameters like flow, temperature, pressure, and composition. A HAZOP study is highly thorough and well-suited for complex, continuous, or semi-continuous processes such as Active Pharmaceutical Ingredient synthesis, solvent recovery, and bioreactor operations.

What-If Analysis

What-If analysis poses open-ended questions about potential process deviations or failures. Teams brainstorm scenarios and evaluate their likelihood and consequences. What-If is faster and more flexible than HAZOP and works well for simpler processes or early design stages.

Failure Modes and Effects Analysis (FMEA)

FMEA examines how individual components or process steps can fail, the effects of those failures, and their detectability. Each failure mode receives a Risk Priority Number (RPN) calculated by multiplying severity, occurrence, and detection scores. FMEA is the preferred method for medical device design risk assessment under ISO 14971 and for pharmaceutical equipment qualification.

Fault Tree Analysis (FTA)

FTA starts with a defined undesirable top event and works backward using Boolean logic to identify the combinations of equipment failures and human errors that could cause it. FTA is particularly useful when a specific high-consequence scenario needs deep analysis.

Checklist Analysis

Checklist analysis uses a predefined list of questions based on established standards, codes of practice, and prior experience. It is the fastest of the PHA methods but is limited to previously identified hazard types.

PHA in Life Sciences: Special Considerations

Pharmaceutical API Manufacturing

In pharmaceutical manufacturing, Active Pharmaceutical Ingredient production often involves flammable solvents, reactive intermediates, and highly potent compounds. HAZOP is the dominant method for API manufacturing PHA. The PHA output connects directly to process validation protocols, engineering controls specifications, and the facility's QMS risk register.

Medical Device Manufacturing and ISO 14971

Medical device manufacturers apply PHA principles at the product design level and the manufacturing process level. At the manufacturing process level, risk assessments evaluate contamination risks, process capability, and equipment-related failure modes that could compromise device safety or performance.

Food and Beverage: HACCP as PHA

For food and beverage manufacturers, HACCP functions as the industry-specific PHA framework. Every food safety plan mandated under FDA FSMA preventive controls must begin with a documented hazard analysis that systematically evaluates biological, chemical, radiological, and physical hazards at each process step.

How to Conduct a Process Hazard Analysis: Step by Step

Step 1: Define the Scope and Process Boundaries

Start by specifying which process or process section the PHA covers. Define the boundaries clearly and gather all relevant process documentation, including P&IDs, process flow diagrams, material safety data sheets, and operating procedures.

Step 2: Assemble the Right Team

A credible PHA requires multidisciplinary expertise. The core team typically includes a process engineer, an operations or production representative, a safety or EHS professional, and a facilitator trained in the chosen PHA method. Under OSHA PSM requirements, at least one team member must have experience in the specific process being analyzed.

Step 3: Identify Hazard Scenarios

Using the chosen method, the team systematically identifies hazard scenarios. Each scenario must be recorded with a description of the deviation or failure, its potential cause, its likely consequence, and the existing safeguards already in place.

Step 4: Evaluate Risk and Existing Safeguards

For each hazard scenario, the team estimates the likelihood of occurrence and the severity of the consequence, taking existing safeguards into account. The team then determines whether the existing safeguards are adequate or whether additional risk reduction measures are needed.

Step 5: Generate and Assign Recommendations

Where existing safeguards are inadequate, the team generates specific recommendations: engineering changes, administrative controls, procedural updates, or additional safeguards. Each recommendation is assigned to an owner with a target completion date.

Step 6: Document the PHA Report

The completed PHA must be thoroughly documented. The PHA report should include the methodology used, the team roster, the date of the study, all worksheets capturing each hazard scenario evaluated, the risk ranking for each scenario, existing safeguards, and all recommendations with their disposition status.

Step 7: Resolve Action Items and Revalidate

PHA is not a one-time activity. Action items must be tracked through completion. OSHA PSM requires that PHA recommendations be resolved promptly and that findings be communicated to affected workers. Revalidation is required every five years under OSHA PSM.

How PHA Outputs Feed Into Your QMS

The value of a PHA multiplies significantly when its outputs are fully integrated into the quality management system.

Risk Register

PHA-identified hazard scenarios with residual risk should be entered into the risk register. Cloudtheapp's Risk Assessments app and Enterprise Risk Management module provide a structured environment to capture, score, and track PHA-derived risks alongside product design risks, supplier risks, and operational risks in a unified register.

CAPA

When a PHA recommendation requires a process modification or a procedural change that addresses an identified hazard, that action is often appropriately managed through a Corrective and Preventive Action workflow. Cloudtheapp's Corrective and Preventive Actions app connects directly to risk assessments, enabling teams to link a CAPA directly to the PHA finding that triggered it.

Change Management

Process changes require a PHA review before implementation. This is the "Management of Change" element of OSHA PSM. Cloudtheapp's Change Management app integrates with risk assessment workflows so that every change request automatically triggers a hazard review step, ensuring no process modification bypasses safety evaluation.

Common PHA Documentation Gaps

Incomplete safeguard documentation. Teams identify hazards but fail to fully document the existing safeguards that justify their risk ranking.

Unresolved recommendations. PHA action items get generated but never formally closed with evidence of implementation.

No linkage to Management of Change. Organizations perform an initial PHA but then allow incremental process changes to accumulate without triggering PHA updates.

Inaccessible or paper-based records. PHA documentation stored in file cabinets or uncontrolled spreadsheets makes it difficult to retrieve during regulatory inspections.

Missing revalidation documentation. Many facilities perform revalidations informally without creating a documented record.

Integrating PHA Into a Modern QMS with Cloudtheapp

Cloudtheapp's AI-powered, no-code QMS platform provides the tools life sciences and manufacturing organizations need to run PHA as a living, integrated process rather than a static compliance document.

The Hazard Analysis app provides structured worksheets for recording and scoring hazard scenarios. The HACCP app supports food safety hazard analysis and critical control point documentation. The Risk Assessments and Enterprise Risk Management modules maintain a live risk register that connects PHA outputs to ongoing risk monitoring.

Because Cloudtheapp is validated to FDA 21 CFR Part 11 and compliant with ISO 13485, ISO 9001, and ISO 22001, all PHA documentation created in the platform carries the audit trail, electronic signature controls, and controlled document status that regulated industries require.

Ready to see how Cloudtheapp connects process hazard analysis to your entire quality system? Request a Demo at cloudtheapp.com to see the platform in action.

Conclusion

Process hazard analysis is one of the most consequential tools in the safety and quality professional's toolkit. It converts potential catastrophes into documented, managed risks. For life sciences and manufacturing companies, PHA sits at the intersection of OSHA process safety compliance, EPA environmental protection, FDA quality system requirements, and ISO risk management standards. Organizations that treat PHA as a living program, one that feeds directly into their QMS risk register, CAPA system, and change management workflow, are better protected, better prepared for regulatory scrutiny, and better positioned to prevent incidents before they occur.

This post created by and appeared first on Cloudtheapp

FMEA (Failure Mode and Effects Analysis) is a structured risk methodology that helps quality teams identify what can go wrong before it does. The right FMEA app automates RPN scoring, links to your risk register and CAPA system, supports electronic signatures, and is fully configurable to your regulatory context. For medical device, pharma, and manufacturing teams, the platform must also support ISO 14971, ICH Q9, and 21 CFR Part 11 compliance requirements. This guide covers FMEA types, regulatory basis, why spreadsheets fail, what to look for in FMEA software, and the questions you should put to every vendor.

What Is FMEA?

Failure mode and effects analysis is a structured, proactive methodology for identifying potential failures in a product, process, or system before they occur. Each potential failure mode is analyzed for its effects, and a Risk Priority Number (RPN) is calculated by multiplying three factors: Severity (S), Occurrence (O), and Detection (D). The result is a prioritized list of risks that guides corrective and preventive action.

The methodology originated in the U.S. military in the late 1950s and has since become a foundational risk tool across life sciences, automotive, manufacturing, aerospace, and food production. Today it functions as both a standalone risk analysis and a key input into broader risk management programs under international standards.

A well-executed FMEA helps quality teams accomplish four things:

• Identify failure modes before they reach the customer or patient
• Quantify and rank risk systematically using RPN
• Prioritize where corrective controls deliver the most value
• Build a traceable record for regulatory submissions and audits

The Three Types of FMEA: DFMEA, PFMEA, and SFMEA

Design FMEA (DFMEA)

DFMEA focuses on the product design itself. It identifies risks introduced by design choices, materials, architecture, interfaces, and intended use before a product enters manufacturing. In medical devices, DFMEA is a critical input to design controls under 21 CFR Part 820 and supports hazard analysis under ISO 14971.

Process FMEA (PFMEA)

PFMEA focuses on the manufacturing or assembly process. It identifies where the process itself could fail to produce a conforming product, addressing factors like equipment, personnel, environment, and materials.

System FMEA (SFMEA)

SFMEA takes a higher-level view, examining failures at the system or subsystem interaction level. It is used during early design phases to evaluate how components interact and where system-level failures could arise.

The Regulatory Basis for FMEA

ISO 14971 for Medical Devices

ISO 14971:2019 requires manufacturers to establish a risk management process covering risk analysis, evaluation, control, and monitoring throughout the device lifecycle. FMEA is one of the most widely used techniques to fulfill the risk analysis requirements of ISO 14971, particularly for design-phase hazard identification.

ICH Q9 for Pharmaceuticals

ICH Q9 on quality risk management explicitly lists FMEA as a recommended tool for pharmaceutical risk programs. FMEA under ICH Q9 supports decisions about process validation, change control, and deviation investigations.

AIAG-VDA for Automotive and Manufacturing

The AIAG-VDA FMEA Handbook sets the standard for the automotive industry. The 2019 edition introduced a revised seven-step approach and updated Severity, Occurrence, and Detection tables.

FDA 21 CFR Part 820 and 21 CFR Part 11

FDA regulations require medical device manufacturers to document risk analysis as part of their design controls. Electronic FMEA records must comply with 21 CFR Part 11 for electronic records and signatures, which requires audit trails, access controls, and validated software.

Why Spreadsheets Fail for FMEA Management

No Version Control or Audit Trail

Spreadsheets circulate by email, and version history is unreliable at best. The absence of a tamper-evident audit trail is a direct noncompliance risk under 21 CFR Part 11.

Manual RPN Calculation Creates Error Risk

Every RPN score depends on three manually entered values. Across dozens or hundreds of failure modes, the risk of calculation errors, inconsistent scoring scales, or stale values is significant.

Isolation from CAPA and Deviations

A FMEA that lives in a spreadsheet is isolated from the rest of the quality system. When a corrective action resolves a failure mode, the FMEA requires a manual update. These gaps create traceability failures that surface during audits.

Electronic Signature Gaps

FDA-regulated environments require electronic signatures that meet 21 CFR Part 11 requirements. Spreadsheets cannot provide compliant e-signatures.

What to Look for in an FMEA App

1. Automated RPN Calculation with Configurable Risk Matrices

The software should calculate RPN automatically from Severity, Occurrence, and Detection inputs and alert the team when scores exceed defined thresholds. The risk matrix should be configurable without code to match your regulatory context.

2. Direct Integration with the Risk Register

FMEA findings should flow directly into your organization's risk register. When your FMEA app links failure modes to a live risk register, your organization's risk profile stays current as new FMEAs are completed, controls are implemented, and residual risk is reassessed.

3. CAPA and Deviation Integration

Every high-RPN failure mode should be able to generate a corrective and preventive action directly from the FMEA record, with a traceable link between both records. Root cause investigation is far more effective when FMEA data is integrated into the same system.

4. Electronic Signatures Compliant with 21 CFR Part 11

FMEA reviews, approvals, and closures require signatures that meet 21 CFR Part 11 requirements. Every action on every record should be logged with a timestamp and user identity.

5. Design Controls Integration for Medical Device Teams

For medical device manufacturers, the FMEA is a design control document. The software should link FMEA records to design inputs, design outputs, and verification and validation activities.

6. A Validated Platform with Compliance Documentation

A purpose-built FMEA app for regulated industries should include a full validation package: IQ, OQ, and PQ documentation for each software version.

7. Support for DFMEA, PFMEA, and SFMEA Workflows

The tool should support all three FMEA types within a single environment, with form templates appropriate to each methodology.

8. Role-Based Access and Collaborative Review

The platform should support role-based access so that design engineers, QA reviewers, and management approvers each work on the records relevant to their function.

Questions to Ask FMEA Software Vendors

1. Is the platform FDA-validated and does it include IQ/OQ/PQ documentation for each platform update?
2. Does the risk matrix support custom scoring scales aligned to ISO 14971, AIAG-VDA, and ICH Q9?
3. How does the FMEA module connect to CAPA, deviations, and the risk register within the same system?
4. Are electronic signatures compliant with 21 CFR Part 11, including audit trail and unique credentials?
5. How are FMEA records linked to design controls and the Design History File?
6. Can risk matrix thresholds and scoring scales be configured without code or custom development?

How Cloudtheapp Handles FMEA in a Validated Quality System

Cloudtheapp includes a dedicated FMEA application available in the Cloudtheapp Store, built for regulated industries and designed to work alongside your full quality program.

The FMEA app connects directly to Risk Assessments, CAPA, Deviations, and Design Controls within the same platform. When a high-RPN failure mode requires action, a CAPA record can be initiated from the FMEA entry, and both records maintain a traceable link. The risk register stays current as FMEAs are completed and reviewed, without manual reconciliation between separate tools.

The risk matrix in Cloudtheapp is fully configurable without code. Medical device teams working under ISO 14971 can define their own severity and probability scales, acceptability criteria, and RPN thresholds directly in the platform using no-code designer tools.

Electronic signatures on all FMEA records meet 21 CFR Part 11 requirements, with a complete, tamper-evident audit trail on every entry, edit, and approval. The Cloudtheapp platform is validated under FDA 21 CFR Part 820, ISO 13485, and ISO 9001, and a full validation package is provided with every platform update.

If your team is still managing FMEA in spreadsheets, or using a standalone tool that does not connect to your QMS, Cloudtheapp is built to solve that problem.

Request a demo at cloudtheapp.com to see how the FMEA app works inside a fully integrated, validated quality management system.

This post created by and appeared first on Cloudtheapp